Abstract
Thrombosis, the blockage of blood vessels with clots, can lead to acute myocardial infarction and ischemic stroke, both leading causes of death. Other than surgical interventions to remove or by pass the blockage, or the generation of collateral vessels to provide a new blood supply, the only treatment available is the administration of thrombolytic agents to dissolve the blood clot. This article describes a comprehensive review of streptokinase (SK). We discuss the biochemistry and molecular biology of SK, describing the mechanism of action, structures, confirmational properties, immunogenecity, chemical modification, and cloning and expression. The production and physico-chemical properties of this SK are also discussed. In this review, considering the properties and characteristics of SK that make it the drug of choice for thrombolytic therapy.
Similar content being viewed by others
References
Collen D, Stump DC, Gold HK (1988) Thrombolytic therapy. Annu Rev Med 39:405–423
Bick RL (1985) Thrombolytic therapy. In: Bick RL (ed) Disorders of homeostasis and thrombosis, principles of clinical practice. Thieme Inc., New York
Collen D, Lijnen JR (1986) The fibrinolytic system in man. Crit Rev Hemat Oncol 4:249–301
Castellino FJ (1981) Recent advances in the chemistry of the fibrinolytic system. Chem Rev 81:431– 446
Collen D (1990) Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med 112:529–538
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group (1992) The Lancet 339:753
Marder VJ (1993) Recombinant streptokinase—opportunity for an improved agent. Blood Coagul Fibrinolysis 4:1039–1040
Paoletti R, Sherry S (eds) (1977) Proceedings of the serono symposia. Thrombosis and Urokinase, vol. 9. Academic Publisher, London: p 257
Bick RL (1992) Disorders of thrombosis and hemostasis; Clinical and Laboratory Practice. ASCP Press, USA
Wu KK, Thiagarajan P (1996) Role of endothelium in thrombosis and hemostasis. Annu Rev Med 47:315–331
Bick RL (1982) Clinical relevance of anti-thrombin-III. Semin Thromb Hemost 8:276–287
Castellino FJ (1984) Biochemistry of human-plasminogen. Semin Thromb Hemost 10:18–23
Francis CW, Marder VJ (1994) Physiological regulation and pathologic disorders of fibrinolysis. In: Colman RW, Hirsh J, Marder VJ, Edwin W, Salzman B (eds) Hemostasis and thrombosis. J.B. Lippincott Company, Philadelphia, pp 1076–1103
Summaria L, Robbins KL (1976) Isolation of human plasmid-derived functionally active light (B) chain capable of forming with streptokinase an equimolar light (B) chain-streptokinase complex with plasminogen activator activity. J Biol Chem 251:5810–5813
Violand BN, Castellino FJ (1976) Mechanism of the urokinase-catalyzed activation of human plasminogen. J Biol Chem 251:3906–3912
Wallen P, Wiman B (1972) Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochem Biophys Acta 257:122–134
Sottrup-Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S (1972) Progress in chemical fibrinolysis and thrombolysis, vol. 3. Raven Press, New York, pp 191–209
Pizzo SV, Schwartz ML Hill RL, McKee PA (1972) The effect of plasmin on the subunit structure of human fibrinogen. J Biol Chem 247:636–645
Blomback B, Hessel B, Iwanaga S, Reuterby J, Blomback M (1972) Primary structure of human fibrinogen and fibrin. I. Cleavage of fibrinogen with cyanogen bromide. isolation and characterization of nh2-terminal fragments of the α (“A”)chain. J Biol Chem 247:1496–1512
Bachmann F (1987) Fibrinolysis. In: Verstaete M, Vermylen J, Lijnen R, Arnout J (eds) Thrombosis and haemostasis, Leuven Univ. Press, Leuven, Belgium, pp 227–235
Collen D (1987) Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 33:77–86
Akoi N, Harpel PC (1984) Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 10:24–41
Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F (1984) Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 64:907–913
Wiman B, Collen D (1978) On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 84:573–578
Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens GJ, Heyneker HL (1985) Cloning and expression of the gene for pro-urokinase in Escherichia coli. Biotechnol 3:923–929
Wiman B, Collen D (1977) Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 78:19–26
Wiman B (1980) On the reaction of plasmin or plasmin streptokinase complex with aprotinin or alpha-2-antitrypsin. Thromb Res 17:143–152
Harpel PC (1973) Studies on human plasma α2-macroglobulin-enzyme interactions: evidence for proteolytic modification of the subunit chain structure. J Exp Med 138:508–521
Harpel PC (1981) Alpha2-plasmin inhibitor and alpha2-macroglobulin–plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest 68:46–55
Rajagopalan S, Gonias SL, Pizzo SV (1985) A non-antigenic covalent streptokinase polyethylene glycol complex with plasminogen activator function. J Clin Invest 75:413–419
Lack CH (1948) Staphylokinase: an activator of plasma protease. Nature 161:559–560
Collen D, DeCock F, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM (1992) Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 6:232–242
Schlott B, Hartmann M, Guhrs KH, Birch-Hirschfeid E, Pohl HD, Vandescheure S, Van De Werf F, Michael A, Collen D, Behnke D (1994) High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnol 12:185
Okada K, Ueshima S, Fukao H, Matsuo O (2001) Analysis of complex formation between plasmin(ogen) and staphylokinase or streptokinase. Arch Biochem Biophys 393:339–341
Smith RA, Dupe RJ, English PD, Green J (1981) Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nat 290:505–508
Schluenring WD, Alagan A, Boidol W, Bringmann P, Petri T, Kratzschmar J, Haendler B, Langer G, Baldus B, Witt W, Donnar P (1992) Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Annals NY Acad Sci 667:395–403
Matsuo O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, Sakai M (1990) Thrombolytic properties of staphylokinase. Blood 76:925–929
Lijnen HR, Vanhoef B, DeCock F, Okada K, Ueshima S, Matsuo O, Collen D (1991) On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 266:11826–11832
Sako T (1985) Overproduction of staphylokinase in Escherichia coli and its characterization. Eur J Biochem 149:557–563
Behnke D, Gerlach D (1987) Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase, a bacterial plasminogen activator. Mol Gen Genet 210:528–534
Nicolini FA, Nichols WW, Mehta JL, Saldeen TGP, Schofield R, Ross M, Player DW, Pohl GB, Mattsson C (1992) Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue plasminogen activator. J Am Coll Cardiol. 20:228–235
Adams DS, Griffin LA, Nachajko WR, Reddy VB, Wei CM (1991) A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor. J Biol Chem 266:8476–8482
Wu XC, Ye RQ, Duan YJ, Wong S-L (1998) Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life. Appl Environ Microbiol 64:824–829
Banerjee A, Chisti Y, Banerjee UC (2004) Streptokinase—a clinically useful thrombolytic agent. Biotechnol Adv 22:287–307
Christensen LR (1945) Streptococcal fibrinolysis: a proteolytic reaction due to serum enzyme activated by streptococcal fibrinolysin. J Gen Physiol 28:363–383
McClintock DK, Bell PH (1971) The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun 43:694–702
Summaria L, Arzadon L, Bernabe P, Robbins KC (1974) The interaction of streptokinase with human, cat, dog, and rabbit plasminogens. The fragmentation of streptokinase in the equimolar plasminogen–streptokinase complexes. J Biol Chem 249:4760–4769
Hummel BCW, Schor JM, Buck FF, Boggiano E, DeRenzo EC (1965) Quantitative enzymic assay of human plasminogen and plasmin with azocasein as substrate. Anal Biochem 11:532–547
Reddy KNN, Markus G (1972) Mechanism of activation of human plasminogen by streptokinase presence of active center in streptokinase–plasminogen complex. J Biol Chem 247:1683–1691
Schick LA, Castellino FJ (1973) Interaction of streptokinase and rabbit plasminogen. Biochemistry 12:4315–4321
Kosow DP (1975) Kinetic mechanism of the activation of human plasminogen by streptokinase. Biochemistry 14:4459–4465
Bajaj AP, Castellano FJ (1977) Activation of human plasminogen by equimolar levels of streptokinase. J Biol Chem 252:492–498
Brockway WJ, Castellino FJ (1974) A characterization of native streptokinase and altered streptokinase isolated from a human plasminogen activator complex. Biochemistry 13:2063–2070
Markus G, Werkheiser WC (1964) The interaction of streptokinase with plasminogen. i. functional properties of the activated enzyme. J Biol Chem 239:2637–2643
Wulf RJ, Mertz ET (1969) Studies on plasminogen. Species specificity of streptokinase. Can J Biochem 47:927–931
McKee RJ, Hargrove CK, Smith AG, Mes H, Thompson A (1971) Precise calibration of a Ge(Li)-spectrometer using a digital to analog converter. Nuclear Instr Meth 92:421–432
Sodetz JM, Brockway WJ, Castellino FJ (1972) Multiplicity of rabbit plasminogen. Physical characterization. Biochemistry 11:4451–4458
Camiolo SM, Thorsen S, Astrup T (1971) Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 138:277–280
Takada A, Ito T, Takada Y (1980) Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot. Thromb Haemost 43:20–23
Violand BN, Byrne R, Castellino FJ (1978) The effect of alpha-, omega-amino acids on human plasminogen structure and activation. J Biol Chem 253:5395–5401
Kim DM, Lee SJ, Kim IC, Kim ST, Byun SM (2000) Asp41–His48 region of streptokinase is important in binding to a substrate plasminogen. Thromb Res 99:93–98
Kim IC, Kim JS, Lee SH, Byun SM (1996) C-terminal peptide of streptokinase, Met369–Pro373, is important in plasminogen activation. Biotechnol Mol Biol Int 40:939–945
Kim DM, Lee SJ, Yoon SK, Byun SM (2002) Specificity role of the streptokinase C-terminal domain in plasminogen activation. Biochem Biophys Res Commun 290:585–588
Zhai P, Wakeham N, Loy JA, Zhang XC (2003) Functional roles of streptokinase C-terminal flexible peptide in active site formation and substrate recognition in plasminogen activation. Biochemistry 42:114–120
Wakeham N, Terzyan S, Zhai PZ, Loy JA, Tang J, Zhang XC (2002) Effects of deletion of streptokinase residues 48–59 on plasminogen activation. Protein Eng 15:753–761
Wu DH, Shi GY, Chuang WJ, Hsu JM, Young KC, Chang CW, Wu HL (2001) Coiled coil region of streptokinase gamma-domain is essential for plasminogen activation. J Biol Chem 276:15025–15033
Sazonova IY, Houng AK, Chowdhry SA, Reed GL (2000) Mechanism of action of a novel Streptococcus uberis plasminogen activator (SUPA). Circulation 102:489
Boxrud PD, Bock PE (2000) Streptokinase binds preferentially to the extended conformation of plasminogen through lysine binding site and catalytic domain interactions. Biochemistry 39:13974–13981
Boxrud PD, Verhamme IMA, Fay WP, Bock PE (2001) Streptokinase triggers conformational activation of plasminogen through specific interactions of the amino-terminal sequence and stabilizes the active zymogen conformation. J Biol Chem 276:26084–26089
Sundram V, Nanda JS, Rajagopal K, Dhar J, Chaudhary A, Sahni G (2003) Domain truncation studies reveal that the streptokinase–plasmin activator complex utilizes long range protein–protein interactions with macromolecular substrate to maximize catalytic turnover. J Biol Chem 278:30569–30577
Shi GY, Chang BI, Chen SM, Wu DH, Wu HL (1994) Function of streptokinase fragments in plasminogen activation. Biochem J 304:235–241
Young KC, Shi GY, Chang YF, Chang BI, Chang LC, Lai MD, Chuang WJ, Wu HL (1995) Interaction of streptokinase and plasminogen—studied with truncated streptokinase peptides. J Biol Chem 270:29601–29606
McCoy HE, Broder CC, Lottenberg R (1991) Streptokinases produced by pathogenic group C Streptococci demonstrate species-specific plasminogen activation. J Infect Dis 164:515–521
De Renzo EC, Siiteri PK, Hutchings BL, Bell PH (1967) Preparation and certain properties of highly purified streptokinase. J Biol Chem 242:533–542
Taylor FB, Botts J (1968) Purification and characterization of streptokinase with studies of streptokinase activation of plasminogen. Biochemistry 7:232–242
Jackson KW, Tang J (1982) Complete amino acid sequence of streptokinase and its homology with serine proteases. Biochemistry 21:6620–6625
Malke H, Roe B, Ferretti J (1985) Nucleotide sequence of the streptokinase gene from Streptococcus equisimilis H46A. Gene 34:357–362
Huang TT, Malke H, Ferretti JJ (1989) Heterogeneity of the streptokinase gene in group A Streptococci. Infect Immun 57:502–506
Malke H (1993) Polymorphism of the streptokinase gene—implications for the pathogenesis of poststreptococcal lomerulonephritis. Zentralbl Bakteriol 278:246–257
Radek JT, Castellino FJ (1989) Conformational properties of streptokinase. J Biol Chem 264:9915–9922
Fabian H, Naumann D, Misselwitz R, Ristau O, Gerlach D, Welfle H (1992) Secondary structure of streptokinase in aqueous solution—a Fourier transform infrared spectroscopic study. Biochemistry 31:6532–6538
Misselwitz R Kraft R, Kostka S, Fabian H, Welfle K, Pfeil W, Welfle H, Gerlach D (1992) Limited proteolysis of streptokinase and properties of some fragments. Int J Biol Macromol 14:107–116
Welfle K, Pfeil W, Misselwitz R, Welfle H, Gerlach D (1992) Conformational properties of streptokinase—differential scanning calorimetric investigations. Int J Biol Macromol 14:19–22
Teuten AJ, Broadhurst RW, Smith RAG, Dobson CM (1993) Characterization of structural and folding properties of streptokinase by NMR-spectroscopy. Biochem J 290:313–319
Conejero-Lara K, Parrado J, Azuaya AI, Smith RAG, Ponting CP, Dobson CM (1996) Thermal stability of the three domains of streptokinase studied by circular dichroism and nuclear magnetic resonance. Protein Sci 5:2583–2591
Parrado J, ConejeroLara F, Smith RAG, Marshall JM, Ponting CP, Dobson C (1996) The domain organization of streptokinase: nuclear magnetic resonance, circular dichroism, and functional characterization of proteolytic fragments. Protein Sci 5:693–704
Beldarrain A, Lopez-Lacomba JL, Kutyshenko VP, Serrano R, Cortijo M (2001) Multidomain structure of a recombinant streptokinase. A differential scanning calorimetry study. J Protein Chem 20:9–17
Markus G, Evers JL, Hobika GH (1976) Activator activities of the transient forms of the human plasminogen·streptokinase complex during its proteolytic conversion to the stable activator complex. J Biol Chem 251:6495–504
Siefring GE, Castellino FJ (1976) Interaction of streptokinase with plasminogen: isolation and characterization of a streptokinase degradation product. J Biol Chem 251:3913–3920
Rodriguez P, Fuentes D, Munoz E, Rivero D, Orta D, Alburquerque S (1994) The streptokinase domain responsible for plasminogen binding. Fibrinolysis 8:276–285
Reed GL, Lin LF, Parhami-Seren B, Kussie P (1995) Identification of a plasminogen binding region in streptokinase that is necessary of the creation a functional streptokinase–plasminogen activator complex. Biochemistry 34:10266–10271
Nihalani D, Kumar R, Rajagopal K, Sahni G (1998) Role of the amino-terminal region of streptokinase in the generation of a fully functional plasminogen activator complex probed with synthetic peptides. Protein Sci 7:637–648
Wang X, Lin X, Loy JA, Tang J, Zhang XC (1998) Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 281:1662–1665
Lizano S, Johnston KH (2005) Structural diversity of streptokinase and activation of human plasminogen. Infect Immun 73:4451–4453
Azuaga AI, Dobson CM, Mateo PL, Conejero-Lara F (2002) Unfolding and aggregation during the thermal denaturation of streptokinase. Eur J Biochem 269:4121–4133
Nihalani D, Sahni G (1995) Streptokinase contains two independent plasminogen-binding sites. Biochem Biophys Res Commun 217:1245–1254
Young KC, Shi GY, Wu DH, Chang LC, Chang BI, Ou CP, Wu HL (1998) Plasminogen activation by streptokinase via a unique mechanism. J Biol Chem 273:3110–3116
Reed GL, Liu L, Houng AK, Matsueda LH, Lizbeth H (1998) Mechanisms of fibrin independent and fibrin dependent plasminogen activation by streptokinase. Circulation 98:199
Robinson BR, Liu L, Houng AK, Sazanova IY, Reed GL (2000) The streptokinase beta domain plays a critical role in activator complex formation and substrate docking. Circulation 102:490
Sazonova IY, Robinson BR, Gladysheva IP, Castellino FJ, Reed GL (2004) α-Domain deletion converts streptokinase into a fibrin-dependent plasminogen activator through mechanisms akin to staphylokinase and tissue plasminogen activator. J Biol Chem 279:24994–25001
Boxrud PD, Bock PE (2004) Conformational and proteolytic activation in the kinetic mechanism of plasminogen activation by streptokinase. J Biol Chem 279:36642–36649
Tillett WS, Garner RL (1933) Fibrinolytic activity of hemolytic streptococci. J Exp Med 58:485–502
Ojalvo AG, Pozo L, Labarta V, Torrens I (1999a) Prevalence of circulating antibodies against a streptokinase C-terminal peptide in normal blood donors. Biochem Biophys Res Commun 263:454–459
Kazmi KA, Iqbal MP, Rahbar A, Mehboobali N (2002) Anti-streptokinase titers and response to streptokinase treatment in Pakistani patients. Int J Cardiol 82:247–251
Regnault V, Helft G, Wahl D, Czitrom D, Vuillemenot A, Papouin G, Roda L, Danchin N, Lecompte T (2003) Anti streptokinase platelet-activating antibodies are common and heterogeneous. J Thromb Hemost 1:1055–1061
Ojalvo AG, Torrens I, Seralena A, de la Fuente J (1999) Recombinant streptokinase with reduced immunoreactivity. Thromb Hemost 77:815–817
Torrens I, Ojalvo AG, Seralena A, de la Fuente J (1999a) Study of antigenic regions of streptokinase. Thromb Hemost 2288, Suppl. S
Torrens I, Ojalvo AG, Seralena A, Hayes O, de la Fuente J (1999b) A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic. Immunol Lett 70:213–218
Coffey JA, Jennings KR, Dalton H (2001) New antigenic regions of streptokinase are identified by affinity-directed mass spectrometry. Eur J Biochem 268:5215–5221
Reed GL, Kussie P, Parhamiseren B (1993) A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments. J Immunol 150:4407–4415
Koide A, Suzuki S, Kobayashi S (1982) Preparation of polyethylene glycol-modified streptokinase with disappearance of binding ability towards antiserum and retention of activity. FEBS Lett 143:73–76
Pautov VD, Anufrieva EV, Ananeva TD, Saveleva NV, Taratina TM, Krakovyak MG (1990) Structural dynamic and functional properties of native and modified streptokinase. Mol Biol 24:35–41
Bean RR, Verhamme IM, Bock PE (2005) Role of the streptokinase α-domain in the interactions of streptokinase with plasminogen and plasmin. J Biol Chem 280:7504–7510
Galler LI (2000) Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy. US patent 6087332
Schotmuller H (1903) Die Artunterscheidung der fur den Menschen pathogenen Streptokokken durch Blutagar. Muench Med Wochenschr 1:849–909
Lancefield RC (1933) A serological differentiation of human and other groups of hemolytic Streptococci. J Exp Med 57:571–595
Feldman LJ (1974) Streptokinase manufacture. In German. German patent DE 2354019
Hagenson MJ, Holden KA, Parker KA, Wood PJ, Cruze JA, Fuke M (1989) Expression of streptokinase in Pichia pastoris yeast. Enzyme Microb Technol 11:650–656
Wong SL, Ye RQ, Nathoo S (1994) Engineering and production of streptokinase in Bacillus subtilis expression–secretion system. Appl Environ Microbiol 60:517–523
Malke H, Ferretti JJ (1984) Streptokinase: cloning, expression and excretion by Escherichia coli. Proc Natl Acad Sci 81:3557–3561
Kapur V, Li LL, Hamrick MR, Plikaytis BB, Shinnick TM, Telenti A, Jacobs WR, Banerjee A, Cole S, Yuen KY, Clarridge III JE, Kreiswirth BN, Musser JM (1995) Rapid mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 119:131–138
Malke H, Gerlach D, Kohler W, Ferretti JJ (1984) Expression of a streptokinase gene from Streptococcus equisimilis in Streptococcus sanguis. Mol Gen Genet 196:360–363
Muller J, Reinert H, Malke H (1989) Streptokinase mutations relieving Escherichia coli K-12 (PRLA4) of detriments caused by the wild-type skc gene. J Bacteriol 171:2202–2208
Estrada MP, Hernandez L, Perez A, Rodríguez P, Serrano R, Rubier AR (1992) High-level expression of streptokinase in Escherichia coli. Biotechnology 10:1138–1142
Muller J, Malke H (1990) Duplication of the streptokinase gene in the chromosome of Streptococcus equisimilis H46A. FEMS Microbiol Lett 72:75–78
Ko JH, Park DK, Kim IC, Lee SH, Byun SM (1995) High-level expression and secretion of streptokinase in Escherichia coli. Biotechnol Lett 17:1019–1024
Pratap J, Rajamohan G, Dikshit KL (2000) Characteristics of glycosylated streptokinase secreted from Pichia pastoris: enhanced resistance of SK to proteolysis by glycosylation. Appl Microbiol Biotechnol 53:469–475
Bernheimer AW, Gillman W, Hottle GA, Pappenheimer AM (1942) An improved medium for the cultivation of hemolytic streptococcus. J Bacteriol 43:495–498
Rosenberger RF, Elsden SR (1960) The yields of Streptococcus faecalis grown in continuous culture. J Gen Microbiol 22:726–739
Von Polnitz W, Sehwick HG, Bickhard JH (1962) (to Behringwerke. 31) SocietA Farmaceutici Italia, Indian Patent 73099, 22
Davies HC, Karush F, Rudd JH (1965) Effect of amino acids on steady-state growth of a group A hemolytic streptococcus. J Bacteriol 89:421–427
Holmström B (1968) Production of Streptokinase in Continuous Culture. Appl Microbiol 16:73–77
Baewald G, Mayer G, Heikel R, Volzke KD, Roehlig R, Decker KL, Koehler W, Gerlach D (1975) Fermentative production of Streptococcus metabolites, especially streptokinase. German patent DD 111096
Van de Rijn I, Kessler RE (1980) Growth characteristics of group A streptococci in a new chemically defined medium. Infect Immun 27:444–448
Ozegowski JH, Gerlach D, Kohler W (1983) Influence of physical parameters on the production of streptococcal extracellular proteins in cultures with stabilized pH: 2. Temperature dependence of extracellular protein production. Zentralbl Bakteriol Microbiol Hyg 254:361–369
Suh H, Kim KH, Kim SS, Han MH (1984) Culture conditions of Streptococcus sp. for streptokinase production. Sanop Misaengmul Hakhoechi 12:224–231
Nemirovich-Danchenko MM, Alekseeva VN, Lebedeva VV, Shashkova NM, Feigel’man BI, Burovaya FI, Smirnova EM (1985) Streptokinase. In Russian. USSR patent SU 1147749
Narciandi RE, Morbe FJ, Riesenberg D (1996) Maximizing the expression of recombinant kringle 1 (Streptokinase) synthesized in Escherichia coli. Influence of culture and induction conditions. Biotechnol Lett 18:1261–1266
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY
Lee SH, Jeong ST, Kim IC, Byun SM (1997) Identification of the functional importance of valine-19 residue in streptokinase by N-terminal deletion and site directed mutagenesis. Biochem Mol Biol Int 41:199–207
Mundada LV, Prorok M, DeFord ME, Figuera M, Castellino FJ, Fay WP (2003) Structure–function analysis of the streptokinase amino terminus (residues 1–59). J Biol Chem 278:24421–24427
Yazdani SS, Mukherjee KJ (1998) Overexpression of streptokinase using a fed-batch strategy. Biotechnol Lett 20:923–927
Yazdani SS, Mukherjee KJ (2002) Continuous culture studies on the stability and expression of recombinant streptokinase in Escherichia coli. Bioprocess Biosyst Eng 24:341–346
Patnaik PR (2000) Principal component analysis for minimal model identification of a noise-affected fermentation: application to streptokinase. Biotechnol Lett 22:393
Malke H, Steiner K, Gase K, Frank C (2000) Expression and regulation of the streptokinase gene. Methods 21:111–124
Chisti Y (1998) Biosafety. In: G Subramanian (ed) Bioseparation and bioprocessing: a handbook, vol. 2, Wiley-VCH, New York, pp 379–415
Pierard L, Bollen A (1990) Development of new thrombolytic agents using recombinant DNA technology. J Biotechnol 15:283–304
Diwedi SK, Hiremath JS, Kerkar PG, Reddy Krishna N, Manjunath CN, Ramesh SS, Prabhavati S, Dhobe M, Singh Kavita, Bhusari P, Rao Raman (2005). Indigenous recombinant streptokinase Vs natural streptokinase in acute myocardial infarction patients: Phase III multicentric randomized double blind trial. Indian J Med Sci 59:200–207
Goa KL, Henwood JM, Langley MS, Clissold SP (1990). Intravenous streptokinase: a reappraisal of its therapeutic use in acute myocardial infarction. Drugs 39:693–719
Gruppo Italiano per lo Studio della Soppravvivenza nell’ Infart miocardico (GISSI-2) (1992) A factorial randomized trial of alteplase vs. streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 339:753–770
The TREMA Group investigators (1999) Multicenter, randomized, comparative study of recombinant vs. natural streptokinase in acute myocardial infarction. Thrombo Hemostat 82:1605–1609
Honloser SH, Zabel M, Kasper W, Thomas M, Just H (1991) Assessment of coronary artery patency after thrombolytic therapy; accurate prediction utilising the combined analysis of three non-invasive markers. J Am Col Cardiol 18:44–49
Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica MR et al (2003) Early thrombolysis for the treatment of acute myocardial infarction: A systematic review and economic evaluation. Health Technol Assess 7:1–136
Dundar Y, Hill R, Dickson R, Walley T (2003) Comparative efficacy of thrombolytics in acute myocardial infarction: A systematic review. QJM 96:103–113
Acknowledgements
The authors are thankful to Andhra University, Visakhapatnam, India and Council of Scientific & Industrial Research (CSIR), New Delhi, India, for providing financial support and awarding a senior research fellowship (Award No. 9/2 (454)/2k2, EMR.I) to Dr. Adinarayana Kunamneni.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kunamneni, A., Abdelghani, T.T.A. & Ellaiah, P. Streptokinase—the drug of choice for thrombolytic therapy. J Thromb Thrombolysis 23, 9–23 (2007). https://doi.org/10.1007/s11239-006-9011-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-006-9011-x